Twin Capital Management Inc. boosted its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 16.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 189,371 shares of the biopharmaceutical company’s stock after purchasing an additional 26,821 shares during the quarter. Twin Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $10,552,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Blue Chip Partners Inc. grew its position in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the period. Keel Point LLC lifted its stake in Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 18 shares in the last quarter. Staley Capital Advisers Inc. lifted its stake in Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares in the last quarter. Shayne & CO. LLC lifted its stake in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares in the last quarter. Finally, Greenleaf Trust lifted its stake in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 39 shares in the last quarter. 69.14% of the stock is owned by institutional investors and hedge funds.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/06/twin-capital-management-inc-boosts-position-in-bristol-myers-squibb-company-bmy.html.
Shares of Bristol-Myers Squibb Company (BMY) opened at $62.22 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The firm has a market capitalization of $101,835.48, a P/E ratio of 21.02, a P/E/G ratio of 2.45 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the firm posted $0.77 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.51%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
Several equities analysts have weighed in on the company. Barclays PLC raised their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group LLC cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a research note on Monday, October 16th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann lifted their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup Inc. lifted their target price on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.93.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.